Analyst Price Target is $27.00
▲ +342.62% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $27.00, with a high forecast of $31.00 and a low forecast of $20.00. The average price target represents a 342.62% upside from the last price of $6.10.
Current Consensus is
Buy
The current consensus among 6 polled investment analysts is to buy stock in Olema Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More
